U.S. FDA Clears Pluristem’s Phase III Study in Treatment of Muscle Injury Following Hip Fracture Surgery
Multinational study expected to include clinical sites in U.S. Israel and Europe, where study has been awarded an $8.7 million grant from European Horizon 2020 Program April 25, 2018 07:00 ET | HAIFA, Israel, April 25, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today that the U.S. [...]